Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

85°
- Benton, AR (72018)
  Today
  
  Partly cloudy. High 86F. Winds SSW at 10 to 20 mph..
  
  Tonight
  
  Partly cloudy. Low 64F. Winds SSW at 10 to 15 mph.
  
  Updated: April 17, 2026 @ 1:38 pm
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2026
Community Calendar

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

31.37 +1.04 (+3.43%)

Streaming Delayed Price Updated: 3:39 PM EDT, Apr 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

April 01, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

March 25, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

February 24, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

February 24, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

February 23, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

January 11, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

December 06, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

November 12, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

November 04, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

August 25, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

August 14, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

August 05, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

June 13, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

June 03, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 29, 2025

From Beam Therapeutics

Via GlobeNewswire

BioMedNewsBreaks — Beam Therapeutics Inc. (NASDAQ: BEAM) to Present New Sickle Cell Data from BEACON Trial at EHA2025

May 23, 2025

Via Investor Brand Network

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 14, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 12, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 06, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

April 05, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

March 27, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces Pricing of Underwritten Offering

March 10, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

March 10, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

February 25, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

February 24, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

January 30, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

January 23, 2025

From Beam Therapeutics

Via GlobeNewswire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

Press Releases about Beam Therapeutics Inc. - Common Stock

Sections

Services

Follow Us